Zentalis Pharmaceuticals, Inc. ZNTL

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
53/100
Moderate

Ranked against 712 peers in Biotechnology

About Zentalis Pharmaceuticals, Inc.

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. The company develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. It also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in … Full ZNTL analysis →

Key strengths

  • Scale Supporting Profitability Profitability at scale is strong (score 0.80), demonstrating competitive advantages.
  • Operating Expense Control OpEx growth is controlled (score 0.61), demonstrating operating leverage.

Key risks

  • Elevated Debt Risk Debt serviceability is weak (score 0.35), raising refinancing risk.
  • Revenue Volatility Signals Weak Stickiness Revenue volatility is high (stability score 0.00), suggesting weak customer stickiness.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Developing
40
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where ZNTL ranks in Biotechnology

Zentalis Pharmaceuticals, Inc. ranks #198 of 713 scored companies in Biotechnology by moat score — the top 28%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
194 Immatics N.V. IMTX 54/100 Moderate
195 Cellectis S.A. CLLS 54/100 Moderate
196 HOOKIPA Pharma Inc. HOOK 53/100 Moderate
197 Maravai LifeSciences Holdings, MRVI 53/100 Moderate
198 Zentalis Pharmaceuticals, Inc. ZNTL 53/100 Moderate
199 Arcus Biosciences, Inc. RCUS 53/100 Moderate
200 Cyclerion Therapeutics, Inc. CYCN 53/100 Moderate
201 Lexicon Pharmaceuticals, Inc. LXRX 53/100 Moderate
202 Cassava Sciences, Inc. SAVA 53/100 Moderate

See every Biotech / Pre-Revenue company ranked by moat score →

How ZNTL scores on the Corporate Default defenses

Pricing Power

Score 40 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 60 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 59 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 46 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 49 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 80 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding ZNTL's moat

What is Zentalis Pharmaceuticals, Inc.'s moat score?

Zentalis Pharmaceuticals, Inc. (ZNTL) scores 53 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as moderate. It ranks #198 of 713 scored companies in Biotechnology, the top 28%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Scale & Market Position (80/100) and its weakest is Pricing Power (40/100).

How does Zentalis Pharmaceuticals, Inc. compare with other Biotechnology companies?

Zentalis Pharmaceuticals, Inc. ranks #198 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Maravai LifeSciences Holdings, (MRVI) at 53 just above it and Arcus Biosciences, Inc. (RCUS) at 53 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Zentalis Pharmaceuticals, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Zentalis Pharmaceuticals, Inc.?

The Corporate Default template measures 6 defenses, and ZNTL scores: Pricing Power (40), Cost Advantage (60), Customer Stickiness (59), Capital Efficiency (46), Resilience (49), Scale & Market Position (80). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000